Niu Yamei, Komatsu Nobukazu, Komohara Yoshihiro, Matsueda Satoko, Yutani Shigeru, Ishihara Yuki, Itou Minoru, Yamada Akira, Itoh Kyogo, Shichijo Shigeki
Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan.
J Med Virol. 2009 Jul;81(7):1232-40. doi: 10.1002/jmv.21518.
C35-44 peptide is a well known HLA-A2-restricted CTL epitope originating from hepatitis C virus (HCV) core protein. It was reported that the majority of HCV positive patients had significant levels of serum IgG specific to this peptide. This study addressed whether C35-44 peptide could induce CTL activity restricted to various HLA class IA alleles or could not. This peptide demonstrated binding activity to HLA-A2402, -A2601, -A3101, and -A3303 molecules, but not to HLA-A1101 by means of stabilization assay. This peptide also induced CTL activity restricted to each of them, except HLA-A11(+) peripheral blood mononuclear cells from HCV 1b(+) patients by means of (51)Cr-release assay. With regard to HLA-A2 subtypes, this peptide demonstrated binding activity to HLA-A0201 and -A0206, but not to -A0207 molecules. Furthermore, this peptide induced CTL activity from both the patients and healthy donors with all the HLA class IA molecules mentioned above by means of interferon-gamma production assay. These results may provide new insights for the development of a novel peptide vaccine against HCV compatible with various HLA class IA types.
C35 - 44肽是一种源自丙型肝炎病毒（HCV）核心蛋白的、众所周知的HLA - A2限制性CTL表位。据报道，大多数HCV阳性患者血清中针对该肽的IgG水平显著。本研究探讨了C35 - 44肽是否能诱导针对各种HLA - I类A等位基因的CTL活性。通过稳定性分析，该肽显示出与HLA - A2402、- A2601、- A3101和- A3303分子的结合活性，但与HLA - A1101无结合活性。通过51Cr释放分析，该肽还诱导了针对上述每种分子的CTL活性，但来自HCV 1b阳性患者的HLA - A11（+）外周血单个核细胞除外。关于HLA - A2亚型，该肽显示出与HLA - A0201和- A0206的结合活性，但与- A0207分子无结合活性。此外，通过干扰素 - γ产生分析，该肽诱导了上述所有HLA - I类A分子的患者和健康供体的CTL活性。这些结果可能为开发一种与各种HLA - I类A类型兼容的新型抗HCV肽疫苗提供新的见解。
